AstraZeneca: Tagrisso Approved in the US for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer
September 27, 2024
September 27, 2024
WILMINGTON, Delaware, Sept. 27 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Based on LAURA Phase III trial results which showed TAGRISSO extended median
progression-free survival by more than three years
* * *
AstraZeneca's TAGRISSO (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-muta . . .
* * *
Based on LAURA Phase III trial results which showed TAGRISSO extended median
progression-free survival by more than three years
* * *
AstraZeneca's TAGRISSO (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-muta . . .